Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
Open accessThe DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The prognoses with respect to mortality and hepatic and nonhepatic outcomes across the histologic spectrum of nonalcoholic fatty liver disease (NAFLD) are not well defined. METHODS: We prospectively followed a multicenter patient population that included the full histologic spectrum of NAFLD. The incidences of death and other outcomes were compared across baseline histologic characteristics. RESULTS: A total of 1773 adults with NAFLD were followed for a median of 4 years. All-cause mortality increased with increasing fibrosis stages (0.32 deaths per 100 person-years for stage F0 to F2 [no, mild, or moderate fibrosis], 0.89 deaths per 100 persons-years for stage F3 [bridging fibrosis], and 1.76 deaths per 100 person-years for stage F4 [cirrhosis]). The incidence of liver-related complications per 100 person-years increased with fibrosis stage (F0 to F2 vs. F3 vs. F4) as follows: variceal hemorrhage (0.00 vs. 0.06 vs. 0.70), ascites (0.04 vs. 0.52 vs. 1.20), encephalopathy (0.02 vs. 0.75 vs. 2.39), and hepatocellular cancer (0.04 vs. 0.34 vs. 0.14). As compared with patients with stage F0 to F2 fibrosis, patients with stage F4 fibrosis also had a higher incidence of type 2 diabetes (7.53 vs. 4.45 events per 100 person-years) and a decrease of more than 40% in the estimated glomerular filtration rate (2.98 vs. 0.97 events per 100 person-years). The incidence of cardiac events and nonhepatic cancers were similar across fibrosis stages. After adjustment for age, sex, race, diabetes status, and baseline histologic severity, the incidence of any hepatic decompensation event (variceal hemorrhage, ascites, or encephalopathy) was associated with increased all-cause mortality (adjusted hazard ratio, 6.8; 95% confidence interval, 2.2 to 21.3). CONCLUSIONS: In this prospective study involving patients with NAFLD, fibrosis stages F3 and F4 were associated with increased risks of liver-related complications and death. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; NAFLD DB2 ClinicalTrials.gov number, NCT01030484.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The risk of future liver-related events starts to increase at fi brosis stage 2.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [122]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The progression to NASH involves hepatocyte damage and liver inflammation, with the development of liver fibrosis being the key determinant of patient outcomes 3-9 .”
From Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“fibrosis stage is predictive of liver-specific morbidity and mortality.”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Ultimately, those with NASH and fibrosis may develop end-stage complications such as cirrhosis, portal hypertension or hepatocellular carcinoma (HCC), which portend a much worse prognosis.6–10”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [6]
In the citing paper
“In patients with MASLD, liver fibrosis represents the primary determinant of mortality [258–261].”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · doi:10.1038/s41423-025-01313-7 · cites this paper as [261]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010 · Cited by 17,796
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
SAUNDERS, J. B., AASLAND, O. G., BABOR, T. F., DE LA FUENTE, J. R., & GRANT, M. (1993) · Addiction · doi:10.1111/j.1360-0443.1993.tb02093.x · Cited by 13,597
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationYounossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationA Model to Predict Survival in Patients With End–Stage Liver Disease
Kamath, P. S., Wiesner, R. H., Malinchoc, M., Kremers, W., Therneau, T. M., Kosberg, C. L., D'Amico, G., Dickson, R. E., & Kim, R. W. (2001) · Hepatology · doi:10.1053/jhep.2001.22172 · Cited by 4,975
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citation2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s002 · Cited by 3,159
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Self-citation
Cited by
Items 501–600 of 1,001
Gabriel-Medina, P., Ferrer, R., Ciudin, A., Augustín, S., Rivera‐Esteban, J., Pericàs, J. M., Selva, D. M., & Rodríguez‐Frias, F. (2023) · Internal and Emergency Medicine · doi:10.1007/s11739-023-03441-2 · Cited by 12
“Liver fibrosis is the strongest predictor of clinically meaningful outcomes, including decompensation, cardiovascular and liver-related morbimortality [8–10].”
BackgroundMichel, M. S., Doll, M., Albert, N., Morgenstern, M., Behr, A., Maxeiner, S., Labenz, C., Galle, P. R., & Schattenberg, J. M. (2024) · United European Gastroenterology Journal · doi:10.1002/ueg2.12511 · Cited by 12
Cheng, W., Chen, H.-F., Cheng, H., & Li, C. (2024) · Epidemiology and Health · doi:10.4178/epih.e2024024 · Cited by 12
The Metabolomic Footprint of Liver Fibrosis
Beyoğlu, D., Popov, Y. V., & Idle, J. R. (2024) · Cells · doi:10.3390/cells13161333 · Cited by 12
“…characteristics, only advanced fibrosis is strongly associated Cells 2024 , 13 , 1333 2 of 28 with an increased risk of liver-related complications and death in NAFLD/NASH [9], strongly suggesting that understanding and therapeutically addressing liver fibrosis is of central importance in MASLD.”
BackgroundDuan, X., Lv, J., Jiang, H., Zheng, K., & Chen, Y. (2022) · Genetics Research · doi:10.1155/2022/8560831 · Cited by 11
Dukewich, M., Dodge, J. L., Yuan, L., & Terrault, N. A. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.09.003 · Cited by 14
Huang, S., Xiao, X., Wu, H., Zhou, F., & Fu, C. (2023) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-023-03529-w · Cited by 10
“Liver fibrosis is an essential link in the progression of liver cancer from NASH [5].”
Kim, G., Park, Y., Oh, S. J., Jung, J., Han, S., Chang, H., Park, S. W., Kim, T. H., Park, H. W., Choe, J., et al. (2023) · Liver International · doi:10.1111/liv.15819 · Cited by 13
“23 Thus, the American Gastroenterological Association guidelines now recommend HCC surveillance for non-cirrhotic NAFLD patients when they have advanced liver fibrosis.”
BackgroundSterling, R. K., Gómez, E. V., Wilson, L., Loomba, R. S., Gawrieh, S., Price, J. C., Naggie, S., Lake, J. E., Heath, S. L., Tonascia, J., et al. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002700 · Cited by 13
“Theseverity of hepatic fi brosis in NAFLD a ff ects survival and liver-related events (14 – 16).”
Self-citationZheng, D., Liu, X., Zeng, W., Zhou, W., & Zhou, C. (2024) · Scientific Reports · doi:10.1038/s41598-024-61696-x · Cited by 15
Saito, T., Tsuchishima, M., Tsutsumi, M., & George, J. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18491 · Cited by 14
Righetti, R., Cinque, F., Volpe, M. T., & Sebastiani, G. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2385487 · Cited by 13
“Indeed, MASLD patients primarily face mortality from cardiovascular disease [3] and develop numerous other comorbidities, including type 2 diabetes mellitus (T2DM) [4], hypertension [5], dyslipidemia [6], and obstructive sleep apnea [7].”
Rodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 13
El‐Kassas, M., Villota‐Rivas, M., Alswat, K., Al-Naamani, K. M., Yilmaz, Y. N., Labidi, A., Sanai, F. M., Awad, A., Akroush, M., Alqahtani, S. A., et al. (2025) · Liver International · doi:10.1111/liv.70108 · Cited by 11
Borges, R. D. S., de Abreu, E. S., Berton, G. G., de Paula, L. H., Conegundes, A. F., Martins, J. M. B., Martins, M. A. B., Dahbour, A., Fernandes, M. V., & Abdelmalek, M. F. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101708 · Cited by 14
“3,9,10 In those with advanced-stage disease, the presence of T2DM is associated with a fourfold higher risk of hepatocellular carcinoma.”
Shinde, S., Nelson, D. R., Mitroi, J., Heaton, P. C., Hincapie, A. L., & Brouwers, B. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2279676 · Cited by 12
“This may partially explain our observations of higher baseline NAS and FS in patients with NAFLD/NASH and T2D.”
BackgroundResultInfluentialNoureddin, N., Huang, D. Q., Bettencourt, R., Siddiqi, H., Majzoub, A. M., Nayfeh, T., Tamaki, N., Izumi, N., Nakajima, A., Idılman, R., et al. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17981 · Cited by 10
Self-citationManagement of Cardiovascular Risk in the Non‑alcoholic Fatty Liver Disease Setting
Luque-Linero, P., & Castilla‐Guerra, L. (2024) · European Cardiology Review · doi:10.15420/ecr.2023.19 · Cited by 14
“9,10 Therefore, although NAFLD has traditionally been interpreted as a liver disease with a high risk of liver-related complications, and most patients have usually been referred to gastroenterologists and hepatologists, patients also have an increased chance of developing CVD, and the landscape of…”
BackgroundSultanik, P., Lherault, G., Bouzbib, C., Ratziu, V., Pais, R., Mouri, S., Thabut, D., & Rudler, M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18165 · Cited by 11
“20 As epidemiology of cirrhosis is changing, as well as global management of cirrhosis during the last 2 decades, including for instance a much large use of transjugular intrahepatic portosystemic shunt (TIPS), we aimed to evaluate the prevalence and the prognosis of MASLD-related cirrhosis in…”
Kim, N. J., Vutien, P., Borgerding, J. A., Beste, L. A., Li, M., Giustini, A. B., Johnson, K. M., & Ioannou, G. N. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003161 · Cited by 10
Koschade, S. E., Moser, L. M., Sokolovskiy, A., Michael, F. A., Serve, H. L., Brandts, C., Finkelmeier, F., Zeuzem, S., Trebicka, J., Ferstl, P. G., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134373 · Cited by 9
“The frequency and severity of cytopenia and the number of affected lineages increase with the progression of liver cirrhosis [3,5,6].”
BackgroundIdentifying and Linking Patients At Risk for MASLD with Advanced Fibrosis to Care in Primary Care
Xiao, T. G., Witek, L., Bundy, R. A., Moses, A., Obermiller, C. S., Schreiner, A. D., Dharod, A., Russo, M. W., & Rudnick, S. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-024-08955-9 · Cited by 14
Guo, Z., Yao, Z., Huang, B., Wu, D., Li, Y., Chen, X., Lu, Y., Wang, L., & Lv, W. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112821 · Cited by 10
Kwan, S., Gonzales, K. A., Jamal, M. A., Stevenson, H. L., Tan, L., Lorenzi, P. L., Futreal, P. A., Hawk, E. T., McCormick, J. B., Fisher‐Hoch, S. P., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2399260 · Cited by 11
Inukai, Y., Ito, T., Yokoyama, S., Yamamoto, K., Imai, N., Ishizu, Y., Honda, T., Shimizu, T., Hattori, M., Takeyama, T., et al. (2024) · Journal of Digestive Diseases · doi:10.1111/1751-2980.13325 · Cited by 10
Wong, R. J., Gagnon‐Sanschagrin, P., Heimanson, Z., Maitland, J., Bellefleur, R., Guérin, A., Samson, A., Olujohungbe, O., & Bumpass, B. (2025) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000823 · Cited by 10
“…cirrhosis than cirrhosis of othercauses and that OHE is one of the most common decompensation events among patients with MASLD (20,21); thus, trends in HE epidemiology will likely continue to be in fl uenced by the evolving epidemiology of the etiologies of liver disease in the…”
Liu, L., Deng, Y., Yang, L., Wang, M., & Lai, Y. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.108998 · Cited by 9
Truong, E., Alnimer, L., GORNBEIN, J. A., Yang, J. D., Alkhouri, N., Harrison, S. A., & Noureddin, M. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-08850-1 · Cited by 10
“To date, the largest prospective study investigating MALO enrolled only 55 patients with MALO with median follow-up time of 4 years, despite even longer ongoing enrollment [7].”
Grueso-Navarro, E., & Lucendo, A. J. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2514605 · Cited by 12
“Stages F3 and F4 were associated with increased risks of liver-related complications and death [124].”
InfluentialManagement of patients with type 2 diabetes and MASLD: An overview and joint statement
Chouik, Y., Canivet, C. M., Julla, J., Mouillot, T., Parlati, L., Rouland, A., Smati, S., Tramunt, B., Anty, R., Boursier, J., et al. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101709 · Cited by 12
Blood metabolic panels for identifying significant fibrosis and inflammation in patients with MASLD
Huang, Y., Li, J., Song, S., Du, B., Cao, Y., Wang, Y., Fu, H., Zhou, T., Yu, S., Liu, Y., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102522 · Cited by 11
“2 6 Therefore, patients with I ≥ 2 or F ≥ 2 are considered to have at-risk MASH.”
InfluentialSung, P. S., Kim, C., Hoon, J., Park, J., Yu, Y. S., Wang, H.-J., Kim, J.-K., & Bae, S. H. (2022) · Biomedicines · doi:10.3390/biomedicines10010180 · Cited by 10
“We defined low-grade and high-grade fibrosis according to the recent report describing significant worse liver-related outcome in patients with F3 and F4 fibrosis [13].”
MethodObesity and its influence on liver dysfunction, morbidity and mortality after liver resection
Kampf, S., Sponder, M., Fitschek, F., Laxar, D., Bodingbauer, M., Binder, C., Stremitzer, S., Kaczirek, K., & Schwarz, C. C. (2023) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-22-291 · Cited by 11
“The presence of NAFLD is associated with an increased risk for developing liver-related complications and hepatocellular cancer (6).”
BackgroundSamuel, S., Abulawi, A., & Malik, R. (2023) · Gastroenterology Insights · doi:10.3390/gastroent14030018 · Cited by 10
Effect of bariatric surgery on NAFLD/NASH: a single-centre observational prospective cohort study
Theel, W. B., Klerk, B. M. B., Dirksmeier-Harinck, F., van Rossum, E. F. C., Kanhai, D. A., Apers, J. A., van Dalen, B. M., de Knegt, R. J., Neecke, B. J., van der Zwan, E. M., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-070431 · Cited by 9
Emerging concepts in the detection of liver fibrosis in non-alcoholic fatty liver disease
Armandi, A., Michel, M. S., Gjini, K., Emrich, T., Bugianesi, E., & Schattenberg, J. M. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2242779 · Cited by 9
“In the progression of NAFLD, NASH has become one of the highest risk factors to develop liver cirrhosis and HCC, especially in those patients with underlying T2DM.”
BackgroundInfluentialWilliams, E. E., Mladenovic, A., Ranginani, D., Weber, R., Samala, N. R., Gawrieh, S., Gómez, E. V., Chalasani, N., & Vuppalanchi, R. (2024) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08272-5 · Cited by 13
“The severity of MASLD is graded on a spectrum and ranges from steatotic liver with no stea-tohepatitis or fibrosis to metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis that can ultimately lead to cirrhosis complicated by portal hypertension [4–6].”
Self-citationVelacur ACE outperforms FibroScan CAP for diagnosis of MASLD
Loomba, R. S., Ramji, A. S., Hassanein, T., Yoshida, E. M., Pang, E., Schneider, C., Curry, M. P., & Afdhal, N. H. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000402 · Cited by 10
“[13,14] Multiple society guidelines advocate for noninvasive tests for the assessment of fibrosis using liver stiffness measurements in patients who are at risk of MASLD and MASH based on the presence of diabetes and/or metabolic syndrome.”
BackgroundSelf-citationSteffani, M., Geng, Y., Pajvani, U. B., & Schwabe, R. F. (2024) · Journal of Clinical Investigation · doi:10.1172/jci179710 · Cited by 11
“Fibrosis may progress to cirrhosis and liver failure and also predisposes one to the development of hepatocellular carcinoma (4, 5).”
BackgroundConserved long noncoding RNA TILAM promotes liver fibrosis through interaction with PML in HSCs
Sun, C., Zhou, C., Daneshvar, K., Saad, A. B., Kratkiewicz, A. J., Toles, B. J., Arghiani, N., Hess, A., Chen, J. Y., Pondick, J. V., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000822 · Cited by 13
Zhang, F., Han, Y., Mao, Y.-H., Zheng, G., Liu, L., & Li, W. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2337739 · Cited by 12
“…are critical factors in determining prognosis, which is essential for selecting appropriate treatment methods and enhancing patient outcomes [36]. it is imperative to detect significant liver fibrosis at the earliest possible stage to manage it during the reversible phase. in a cohort study…”
BackgroundSamala, N. R., Kulkarni, M., Lele, R. S., Gripshover, T. C., Wise, J. L., Rai, S. N., & Cave, M. C. (2024) · Toxicological Sciences · doi:10.1093/toxsci/kfae106 · Cited by 11
Shi, R., Chai, K., Wang, H., Zhou, J., Yang, S., Li, J., Qiao, C., Sheng, X., Zhang, X., & Wu, J. (2025) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.70002 · Cited by 11
Pennisi, G., Maria, G. D., Enea, M., Vaccaro, M., Celsa, C., Antonucci, M., Ciancimino, G., Ciccioli, C., Infantino, G., Mantia, C. L., et al. (2025) · Liver International · doi:10.1111/liv.70056 · Cited by 11
Prognostication in NAFLD: physiological bases, clinical indicators, and newer biomarkers
Terracciani, F., Falcomatà, A., Gallo, P., Picardi, A., & Gentilucci, U. V. (2022) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-022-00934-0 · Cited by 9
“More recently, a large prospective longitudinal cohort study was carried out on 1773 patient with biopsy-proven NAFLD followed up for a median period of 4 years [10].”
BackgroundStrnad, P., & Martín, J. S. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2239707 · Cited by 9
ACE inhibitors: The secret to prevent cirrhosis complications and HCC in NAFLD?
Noureddin, M., & Abdelmalek, M. F. (2022) · Hepatology · doi:10.1002/hep.32399 · Cited by 9
“NAFLD, and its progressive form NASH, is currently the leading cause of chronic liver disease worldwide, accounting for an alarming increase in prevalence of cirrhosis, HCC, hepatic decompensation, and need for liver transplantation.[1] Risk factors for acquisition and progression of NAFLD/NASH include features of met…”
BackgroundInfluentialMASLD: predictive value for liver-related events and extra-hepatic complications
Jamalinia, M., & Lonardo, A. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2435504 · Cited by 9
Chen, V. L., Oliveri, A., Raut, C., Chen, Y., Cushing, K. C., & Speliotes, E. K. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003169 · Cited by 10
Aberrant basement membrane production by HSCs in MASLD is attenuated by the bile acid analog INT-767
Ramachandran, P., Brice, M., Sutherland, E. F., Hoy, A. M., Papachristoforou, E., Li, J., Turner, F. S., Kendall, T. J., Marwick, J. A., Carragher, N. O., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000574 · Cited by 9
Li, D., Chen, J., Ye, C., Lin, B., Zhang, T., Chen, Q., Yu, C., & Wan, X. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156369 · Cited by 10
Change in cT1 Following Interventions in MASLD: A Systematic Review and Meta-Analysis
Andersson, A., Loomba, R. S., Beyer, C., Mouchti, S., Vuppalanchi, R., Harisinghani, M. G., Ajaz, S., Dinani, A. M., Banerjee, A., Muthiah, M. D., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.03.003 · Cited by 13
Self-citationGuía de práctica clínica multidisciplinar de manejo de la esteatosis hepática metabólica
Romero‐Gómez, M., Escalada, J., Noguerol, M., Pérez, A., Carretero, J., Crespo, J., Mascort, J. J., Aguilar, I., Tinahones, F. J., Cañones, P., et al. (2025) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2025.502442 · Cited by 9
Liu, B. D. X., Aly, M., Lin, C. H.-T., Panesar, N., Hill, H., & Qureshi, K. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.04.017 · Cited by 10
Messer, E. K., Petroff, D., Schattenberg, J. M., Zeuzem, S., von der Ohe, M., Ludwig, L., Demir, M., Buggisch, P., Stein, K., Serfert, Y., et al. (2025) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2592-6109 · Cited by 11
Hartman, M. L., Loomba, R. S., Lawitz, E., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Tang, Y., Brouwers, B., Bunck, M. C. M., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101472 · Cited by 10
Self-citationBertot, L. C., Sòria, A., Jiménez-Masip, A., Serra, I., Broquetas, T., Vergara, M., Rodríguez-Castellano, A., Aracil, C., Maimouni, C. E., Muñoz, S., et al. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70215 · Cited by 8
“Survival and quality of life among patients with MASLD-related cirrhosis fall markedly once decompensation occurs, with a median survival of approximately 2 years [9].”
Impact of first and further decompensation in patients with compensated ACLD due to MASLD
Pennisi, G., Maria, G. D., Wong, V. W., de Lédinghen, V., Sebastiani, G., Viganò, M., Fracanzani, A. L., Miele, L., Bugianesi, E., Ekstedt, M., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.06.014 · Cited by 10
“11,22 We observed a relatively low rate of HE, in contrast to a recent US cohort where HE was more prevalent 27 – possibly due to differences in baseline characteristics, including a higher prevalence of obesity in the US population, which may predispose to cerebrovascular events.”
Jeong, J., Han, S., Park, G., Park, S.-W., Jeon, Y., Lim, S., Kwon, W. J., Choi, S. H., & Park, N. H. (2025) · Scientific Reports · doi:10.1038/s41598-025-10380-9 · Cited by 8
“Fourth, although previous studies have indicated that fibrosis burden is a key determinant of prognosis in NAFLD 12,39 , a prospective study found no significant association between advanced hepatic fibrosis and the incidence of cardiovascular diseases 38 .”
Loomba, R. S., Clark, V., Mandorfer, M., Miravitlles, M., Brantly, M., Karpen, S. J., Krag, A. A., Kwo, P. Y., Rockey, D. C., Russo, M. W., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.12.012 · Cited by 8
Self-citationTamaki, N., Kimura, T., Wakabayashi, S., Yamazaki, T., Iwadare, T., Tanaka, N., & Kurosaki, M. (2026) · Japanese Journal of Radiology · doi:10.1007/s11604-025-01930-2 · Cited by 11
“In MASLD, non-liver causes, particularly cardiovascular disease and extrahepatic cancers, often dominate mortality, except in those with advanced fibrosis or cirrhosis [ 40, 44, 45].”
Swain, M. G., Pettersson, B., Meyers, O. I., Venerus, M., & Oscarsson, J. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000036 · Cited by 10
Dabbah, S., Yakov, G. B., KAUFMANN, M.-I., Cohen‐Ezra, O., Likhter, M., Davidov, Y., & Ben‐Ari, Z. (2023) · Minerva Gastroenterology · doi:10.23736/s2724-5985.23.03518-0 · Cited by 9
Yamagata, M., Tsuchishima, M., Saito, T., Tsutsumi, M., & George, J. (2024) · Clinical Science · doi:10.1042/cs20230533 · Cited by 8
Choi, S. J., Yoon, S., Kim, K. K., Kim, D., Lee, H., Kim, K. G., Shin, S. K., Park, I. B., Kim, S. M., & Lee, D. H. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0189 · Cited by 9
“Additionally, increases in the grade of fibrosis are associated with adverse clinical outcomes and all-cause mortality [5].”
Gosnell, J., Golovko, G., Arroyave, E., Moghe, A., Kueht, M., Saldarriaga, Ó. A., McKinney, K. H., Stevenson, H. L., & Ferguson, M. R. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i5.886 · Cited by 9
Niu, J., Al-Yaman, W. A., Pinyopornpanish, K., Park, J. S., Salazar, M. J., Xiao, H., Bena, J., Lyu, R., Flocco, G., Junna, S., et al. (2024) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph21060708 · Cited by 10
“It is widely acknowledged that a higher degree of fibrosis is associated with worse disease burden from MASH [4,6,7].”
BackgroundSchreiner, A. D., Zhang, J., Moran, W. P., Koch, D., Marsden, J. E., Bays, C., Mauldin, P. D., & Gebregziabher, M. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.08.002 · Cited by 8
Bassegoda, O., Rivera‐Esteban, J., Serra, I., Morillas, R. M., Broquetas, T., Vergara, M., Rodríguez-Castellano, A., Aracil, C., Virolés, S., Carrión, J. A., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.2056 · Cited by 9
“[22] In a recent prospective study of the full spectrum of NAFLD with a median follow- up time of 4 years, the authors found 37 hepatic decompensating events, 17 events among patients with F4 stage, and 17 among F3.[10] This latter study reported only three events among patients with lower fibrosis stages, underlining…”
BackgroundInfluentialFujii, H., Fujii, M., Iwaki, M., Hayashi, H., Toyoda, H., Oeda, S., Hyogo, H., Kawanaka, M., Morishita, A., Munekage, K., et al. (2023) · Hepatology Research · doi:10.1111/hepr.13884 · Cited by 12
“Although several studies have examined NAFLD‐related HCC, it remains unclear whether the presence of NASH is an independent contributor to HCC occurrence.(11,43,44) In the CLIONE study, the incidence rate of HCC among patients with NAFLD and NASH were 0.”
Dunn, W., Castéra, L., & Loomba, R. S. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.020 · Cited by 8
Self-citationHe, Y., Cao, L., Zhou, C.-P., Zhang, R., Zeng, M., Peng, X., Sun, X., & Yan, J. (2023) · Translational Pediatrics · doi:10.21037/tp-23-123 · Cited by 9
“Previous studies have reported that as the adipose tissue of patients with fatty liver has insulin deficiency or insulin resistance, the surrounding fat breaks down and releases large quantities of free fatty acids and triglycerides, further depositing fat in the liver (39).”
Schreiner, A. D., Zhang, J., Moran, W. P., Koch, D., Marsden, J. E., Livingston, S., Bays, C., Mauldin, P. D., & Gebregziabher, M. (2023) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001935 · Cited by 7
Zhang, J., Chen, K., & Chen, F. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.101077 · Cited by 10
“Hepatic encephalopathy is the most prevalent liver complication in patients with advanced stages (F3/F4) of NAFLD [23].”
Goyal, T., Song, M. W., Suresh, D., Jasty, V. S. J., Urias, E., Wijarnpreecha, K., Wong, Y. J., & Chen, V. L. (2024) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08683-4 · Cited by 10
“Fibrosis is the primary risk factor for liver-related outcomes in MASLD [4–8].”
Kowada, A. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-080549 · Cited by 9
Bera, C., Hamdan‐Pérez, N., Kosick, H. M.-K., Shengir, M., Sebastiani, G., & Patel, K. (2025) · Canadian Liver Journal · doi:10.3138/canlivj-2024-0063 · Cited by 8
Lv, J., Yao, J., Zheng, L., Shao, J., Jin, J., Zheng, Q., Teng, J., Zhou, J., Cai, F., Huang, P., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01715-7 · Cited by 7
“Studies indicate that NAFLD, particularly in severe forms, significantly increases all-cause mortality risk [10, 11].”
Liang, Z., Li, Z., Jin, H., Gao, W., Li, R., Hu, X., Liu, Z., Li, X., Cheng, Y., Guo, L., et al. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5c00190 · Cited by 7
Zhang, H., Lin, F., Miao, M., Yu, C., & Guo, W. Y. (2025) · Nutrition & Metabolism · doi:10.1186/s12986-025-00951-y · Cited by 7
Xu, T., & Zhu, W. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112418 · Cited by 9
Maior, M. D. R. M. S., Ribeiro, N. D. L. I., Silva, H. V. V., Lopes, E. P., & Costa, E. C. (2025) · Biomedicines · doi:10.3390/biomedicines13092162 · Cited by 10
“Sanyal,2021[76] ,including 1773patientswithNAFLD(withor withoutfibrosis).”
Kim, D. Y., Zhang, H., Lee, J. S., Lee, H. W., Kim, M. N., Kim, B. K., Kim, S. U., Kim, D. Y., Ahn, S. H., Lee, H. W., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101713 · Cited by 9
Simonetto, D. A., Rushlow, D. R., Liu, K., Calleri, A., Kassmeyer, B. A., Lennon, R. J., Rattan, P., Bernard, M., Singh, G., Deyo-Svendsen, M. E., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-04058-y · Cited by 10
“CLD with advanced fibrosis was chosen as the primary endpoint owing to its established association with increased risk of liver-related complications and death 41,42 .”
Kim, D. H., Ko, D., Chen, V. L., Porres, J. A., Alatorre, C. E., Nieto, L. M., Argueta, P. P., Kröner, P. T., Lukens, F. J., Kim, D., et al. (2025) · Liver International · doi:10.1111/liv.70490 · Cited by 9
“Once cirrhosis is established, the risk of liver-related events and death rises [38], making hepatic de-compensation and MALO the most common causes of death in these patients [39].”
Tincopa, M. A., Speliotes, E. K., Valenti, L. V. C., & Loomba, R. S. (2026) · Annual Review of Medicine · doi:10.1146/annurev-med-050324-124753 · Cited by 8
Self-citationJiménez-Masip, A., Broquetas, M. T., Muñoz, S., Serra-Matamala, I., Rojo, D., Sòria, A., Maimouni, C. E., Pagès, L., Pons, M., Carrión, J. A., et al. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000000919 · Cited by 7
“[4,5] 6] Current treatment focuses on managing metabolic comorbidities, as there are no approved etiological therapies for MASLD-related cirrhosis.”
Sharpton, S. R., Díaz, L. A., Pepin, K. M., Amangurbanova, M., Madamba, E. V., Bettencourt, R., Singh, S., Valasek, M. A., Dalupang, M., Tesfai, K., et al. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70696 · Cited by 8
Self-citationLi, F., Li, H., Juramt, D., Kou, K., Tacke, F., & Chen, L. (2026) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2026-002343 · Cited by 11
“21 In a prospective study of 1773 adults with MASLD, all-cause mortality was 0.89 per 100 person-years in patients with F3 fibrosis and 1.76 per 100 person-years in those with F4 fibrosis 25 ; meanwhile, fibrosis regression was reported to reduce the risk of liver-related events.”
InfluentialIshiba, H., Sumida, Y., Kamada, Y., Fujii, H., Iwaki, M., Hayashi, H., Toyoda, H., Oeda, S., Hyogo, H., Kawanaka, M., et al. (2023) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16144 · Cited by 7
Gu, L., Yin, X., Cheng, Y., Wang, X., Zhang, M., Zou, X., Wang, L., Zhuge, Y., & Zhang, F. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13040682 · Cited by 9
“Hepatic encephalopathy (HE) was the most frequent first decompensating event in a prospective study of 1773 participants with nonalcoholic fatty liver disease (NAFLD) [5].”
BackgroundInfluentialAlleviation of Hepatic Steatosis by Alpha-Defensin Is Associated with Enhanced Lipolysis
Maraga, E., Safadi, R., Amer, J., Higazi, A. A., & Fanne, R. A. (2023) · Medicina · doi:10.3390/medicina59050983 · Cited by 7
“Previous studies have shown a high prevalence of NAFLD in individuals with hepatomegaly or type 2 diabetes (T2D), both associated with elevated levels of blood glucose and insulin resistance [10].”
BackgroundLi, J., Wang, Q., Ni, W., Liu, C., Li, Z., & Qi, X. (2023) · Global Transitions · doi:10.1016/j.glt.2023.09.002 · Cited by 10
Prevalence and Crucial Parameters in Diabesity-Related Liver Fibrosis: A Preliminary Study
Suwała, S., Białczyk, A., Koperska, K., Rajewska, A., Krintus, M., & Junik, R. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12247760 · Cited by 8
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
Hong, H., & Choi, J. (2024) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2024.048 · Cited by 7
Pompili, E., Baldassarre, M., Iannone, G., Tedesco, G., Nardelli, S., Piano, S. S., Alessandria, C., Neri, S., Foschi, F. G., Levantesi, F., et al. (2024) · Liver International · doi:10.1111/liv.16020 · Cited by 9
Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease
Katsarou, A., Tsioulos, G., Kassi, E. N., & Chatzigeorgiou, A. (2024) · HORMONES · doi:10.1007/s42000-024-00588-1 · Cited by 9
Tea intake and non-alcoholic fatty liver disease risk: A two-sample Mendelian randomization study
Lu, C., Ke, L., Mentis, A. A., Zhang, Q., Wang, Z., & Wang, Z. (2024) · Metabolism Open · doi:10.1016/j.metop.2024.100322 · Cited by 8
“One prospective study [7] demonstrated that NAFLD was associated with all-cause mortality in adult patients and was increased with the fibrosis stage.”
BackgroundInfluentialYan, Y., Gan, D., Ping, Z., Zou, H., & Li, M. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e38848 · Cited by 7
“Identifying individuals at risk of developing NASH is the cornerstone of clinical care and interventions [4].”
BackgroundZhao, W., Mori, H., Tomiga, Y., Tanaka, K., Perveen, R., Mine, K., Inadomi, C., Yoshioka, W., Kubotsu, Y., Isoda, H., et al. (2022) · Genes · doi:10.3390/genes13071265 · Cited by 7
Metadata
- Authors
- Sanyal, A. J., Van Natta, M. L., Clark, J., Neuschwander-Tetri, B. A., Diehl, A., Dasarathy, S., Loomba, R., Chalasani, N., Kowdley, K., Hameed, B., Wilson, L. A., Yates, K. P., Belt, P., Lazo, M., Kleiner, D. E., Behling, C., & Tonascia, J.
- Affiliations
- National Institutes of Health (US)
- From the Virginia Commonwealth University School of Medicine, Richmond (A.J.S.); the Bloomberg School of Public Health, Johns Hopkins University, Baltimore (M.L.V.N., J.C., L.A.W., K.P.Y., P.B., M.L., J.T.), and the Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda (D.E.K.) — both in Maryland; Saint Louis University, St. Louis (B.A.N.-T.); Duke University, Durham, NC (A.M.D.); Cleveland Clinic, Cleveland (S.D.); the University of California, San Diego, School of Medicine, La Jolla (R.L., C.B.), and the University of California, San Francisco, School of Medicine, San Francisco (B.H.); Indiana University School of Medicine, Indianapolis (N.C.); and the Liver Institute Northwest, Seattle (K.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-10-21
- Volume
- 385
- Issue
- 17
- Pages
- 1559-1569
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8881985
- OpenAlex
- W3206948891
- Cited by
- 1,146
- References
- 29
- Citations by year
- 2026: 215 · 2025: 270 · 2024: 266 · 2023: 236 · 2022: 153 · 2021: 3
- FWCI
- 118.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK061713, U01DK061718, U01DK061728, U01DK061731)
- National Center for Advancing Translational Sciences (UL1TR000439, UL1TR000436, UL1TR000006, UL1TR000448)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- non-alcoholic fatty liver disease, liver fibrosis, all-cause mortality, liver complications, hepatic decompensation, variceal bleeding, ascites, hepatic encephalopathy, hepatocellular carcinoma, liver cirrhosis, bridging fibrosis, type 2 diabetes, estimated glomerular filtration rate, cardiac events, prognosis
- MeSH terms
- Adult, Biopsy, Female, Gastrointestinal Hemorrhage, Carcinoma, Hepatocellular, Humans, Liver, Liver Cirrhosis, Liver Neoplasms, Male, Middle Aged, Prognosis, Prospective Studies, Severity of Illness Index, Incidence, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.